Purpose: The goal of is this study is to better understand the real world experience for the use of vedolizumab in the treatment of pediatric Crohn’s disease
Primary/ Secondary Outcomes
- Primary Outcome: Clinical remission rates at 1 year
- Secondary Outcome: Significant baseline factors that predict response to vedolizumab and effect on growth parameters at 1 year
Funding Source: N/A
Study Period:Aug 2020-Jan 2021
Recruitment Status: This study makes use of existing data in the ICN registry. No patient recruitment at this time.
Contact: ImproveCareNow Research